All In Biotech

Drug Trial Radar · NCT02065869

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders

Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

187

Actual

Start

Apr 2014

Primary completion

Jun 2020

Study completion Sep 7, 2021

Sponsor

Lead sponsor
Bellicum PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (Graft versus host disease).

Conditions

  • Acute Lymphoblastic Leukemia
  • Leukemia, Acute Myeloid (AML), Child
  • Lymphoma, Non-Hodgkin
  • Myelodysplastic Syndrome
  • Primary Immunodeficiency
  • Anemia, Aplastic
  • Osteopetrosis
  • Hemoglobinopathies
  • Cytopenia
  • Fanconi Anemia
  • Diamond Blackfan Anemia
  • Thalassemia
  • Anemia, Sickle Cell

Interventions

  • BPX-501 T cellsBiological

    1x10E6 cells/kg infused on Day 0

  • RimiducidDrug

    0.4mg/kg administered IV to treat GVHD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival (EFS) at 180 Days After TransplantTime frame: 180 days after transplant

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Roma, Italy

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

  • Institute of Child Health & Great Ormond Street Hospital

    London, United Kingdom

  • Great North Children's Hospital

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.